Rhode Island Governor Dan McKee has nominated Michelle Reddish to serve as the new chair of the state’s Rhode Island Cannabis Control Commission. The nomination, announced on Tuesday, aims to fill a leadership vacancy that has persisted for over seven months, following the resignation of former Chairperson Kim Ahern last October. Reddish’s appointment comes at a critical juncture for the state’s cannabis industry, particularly as the retail licensing process faces a federal court-ordered halt.
Leadership Appointment and Regulatory Experience
Michelle Reddish has been serving as the administrator of the Rhode Island Cannabis Office since her appointment by Governor McKee in 2024. In a statement, Governor McKee credited Reddish with demonstrating a “deep understanding of Rhode Island’s cannabis landscape” and highlighted her expertise in regulatory compliance, development, and technological advancement. The proposed annual salary for the chairperson position is $204,069, as reported by Marijuana Moment.
Reddish’s nomination now proceeds to the Rhode Island Senate for consideration and confirmation. Upon her nomination, Reddish stated her commitment to supporting safety, transparency, and equity within the state’s cannabis sector.
Reddish’s Background and Contributions
Before her current role, Reddish was instrumental in developing Rhode Island’s cannabis regulatory framework. Her contributions include:
- Developing rules pertaining to retail cannabis operations.
- Establishing the Cannabis Office as the operational arm for the Rhode Island Cannabis Control Commission.
- Administering the initial application process for cannabis retail licenses.
Prior to her work in Rhode Island, Reddish held significant positions in other regulated cannabis markets. She served as the chief operating officer and, before that, chief regulatory officer for the Oklahoma Medical Marijuana Authority. From April 2021 to March 2022, she was the director of compliance for C3 Industries, a Michigan-based cannabis grower and retailer with operations in Massachusetts and Missouri. Her professional background also includes roles as a regulatory compliance officer for Ravago Chemicals and SLB, a global technology company.
Academically, Reddish holds two master’s degrees from Tulane University, one in occupational health and safety and another in cell and molecular biology. She also earned a third master’s degree in health care management from the University of New Orleans.
Context of Retail Cannabis Licensing
The nomination occurs while Rhode Island’s cannabis retail license application process is suspended. In April, a federal judge issued an order halting the process due to three ongoing lawsuits challenging the state’s requirement that cannabis license holders be majority-owned by Rhode Island residents. As previously reported by Hemp Gazette, this issue of residency requirements has been a point of legislative focus.
Before the halt, state regulators were reviewing 97 applications for 20 new retail licenses. The state has appealed the federal judge’s ruling, and a hearing to establish a briefing schedule for the appeal is set for June 23 at the 1st U.S. Circuit Court of Appeals in Boston.
Implications for the Rhode Island Cannabis Control Commission
If confirmed, Reddish will lead the Rhode Island Cannabis Control Commission during a period requiring navigation of complex legal and regulatory challenges. Her experience in establishing regulatory frameworks and managing licensing processes will be relevant as the state addresses the federal court’s intervention and seeks to clarify the future of its retail cannabis market. The Commission’s role in supporting a compliant and equitable industry will be central to resolving the current licensing uncertainties.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
